Department of Social Medicine, Division of Environmental Medicine and Population Sciences, Graduate School of Medicine, Osaka University, Suita, Japan.
Biomedical Statistics, Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
J Alzheimers Dis. 2024;100(3):987-998. doi: 10.3233/JAD-240113.
Previous studies have shown a possible association between statin use and a decreased risk of dementia, but the association has not been sufficiently established, especially in the super-aging society of Japan.
This study aimed to determine the association between statin use and the risk of dementia among Japanese participants aged> =65 years old.
Data from the Longevity Improvement and Fair Evidence (LIFE) Study were utilized, including medical and long-term care (LTC) claim data from 17 municipalities between April 2014 and December 2020. A nested case-control study was conducted with one case matched to five controls based on age, sex, municipality, and year of cohort entry. We used a conditional logistic regression model to calculate the odds ratios (ORs) and 95% confidence intervals (95% CIs).
This study included 57,302 cases and 283,525 controls, with 59.7% of the participants being woman. After adjusting for potential confounders, statin use was associated with a lower risk of dementia (OR, 0.70; 95% CI: 0.68-0.73) and Alzheimer's disease (OR: 0.66; 95% CI: 0.63-0.69). Compared with non-users, the ORs of dementia were as follows: 1.42 (1.34-1.50) for 1-30 total standardized daily dose (TSDD), 0.91 (0.85-0.98) for 31-90 TSDD, 0.63 (0.58-0.69) for 91-180 TSDD, and 0.33 (0.31-0.36) for >180 TSDD in dose-analysis.
Statin use is associated with a reduced risk of dementia and Alzheimer's disease among older Japanese adults. A low cumulative statin dose is associated with an increased risk of dementia, whereas a high cumulative statin dose is a protective factor against dementia.
先前的研究表明,他汀类药物的使用与痴呆风险降低之间可能存在关联,但这种关联尚未得到充分证实,尤其是在日本这个超老龄化社会。
本研究旨在确定他汀类药物的使用与日本≥65 岁参与者痴呆风险之间的关联。
本研究使用了长寿改善和公平证据(LIFE)研究的数据,包括 2014 年 4 月至 2020 年 12 月期间 17 个市的医疗和长期护理(LTC)报销数据。采用基于年龄、性别、市和队列入组年份的 1 例病例与 5 例对照的嵌套病例对照研究。使用条件逻辑回归模型计算比值比(OR)和 95%置信区间(95%CI)。
本研究纳入了 57302 例病例和 283525 例对照,其中 59.7%的参与者为女性。在调整了潜在混杂因素后,他汀类药物的使用与痴呆(OR,0.70;95%CI:0.68-0.73)和阿尔茨海默病(OR:0.66;95%CI:0.63-0.69)风险降低相关。与未使用者相比,痴呆的 OR 如下:总标准化日剂量(TSDD)1-30 为 1.42(1.34-1.50),31-90 为 0.91(0.85-0.98),91-180 为 0.63(0.58-0.69),>180 为 0.33(0.31-0.36)。
在日本老年成年人中,他汀类药物的使用与痴呆和阿尔茨海默病风险降低相关。低累积他汀类药物剂量与痴呆风险增加相关,而高累积他汀类药物剂量是痴呆的保护因素。